abrocitinib
Cibinqo
Pharmaceutical company: Pfizer, Inc.
NEW INDICATION & DOSAGE
Refractory, moderate-to-severe atopic dermatitis not adequately controlled with other systemic drug products, including biologics, or when use of those therapies is inadvisable
Children age 12 and older: 100 mg PO once daily. May increase to 200 mg once daily if inadequate response after 12 weeks. Discontinue the drug if inadequate response after 200-mg dose increase. Can use with or without topical corticosteroids.
Adjust-a-dose: For patients with moderate kidney impairment (eGFR of 30 to 59 mL/min) or patients who are known or suspected CYP2C19 poor metabolizers, reduce dosage to 50 mg once daily; if inadequate response after 12 weeks, may double the dose. Refer to the manufacturer’s instructions for toxicity-related dosage adjustments.
Released: April 2023
Nursing Drug Handbook
© 2023 Wolters Kluwer
aflibercept
Eylea
Pharmaceutical company: Regeneron Pharmaceuticals, Inc.
NEW INDICATION & DOSAGE
Retinopathy of prematurity
Preterm infants: 0.4 mg (0.01 mL) intravitreal injection. May be given bilaterally on the same day. May repeat injection in each eye. Interval between doses injected into the same eye should be at least 10 days.
Released: April 2023
Nursing Drug Handbook
© 2023 Wolters Kluwer
lanadelumab-flyo
Takhzyro
Pharmaceutical company: Takeda Pharmaceuticals U.S.A.
NEW INDICATION & DOSAGE
Prevention of hereditary angioedema attacks
Children age 6 to less than 12 years: Initially, 150 mg subcut every 2 weeks. If the patient is attack-free for more than 6 months, may consider decreasing dosing to 150 mg subcut every 4 weeks.
Children age 2 to less than 6 years: 150 mg subcut every 4 weeks.
Released: April 2023
Nursing Drug Handbook
© 2023 Wolters Kluwer
sildenafil
Revatio
Pharmaceutical company: Viatris Specialty LLC
NEW INDICATION & DOSAGE
To improve exercise ability and delay clinical worsening in patients with World Health Organization group 1 pulmonary arterial hypertension
Children ages 1 to 17 weighing more than 45 kg: 20 mg PO t.i.d. Dose may be titrated to a maximum dose of 40 mg t.i.d. based on symptoms and tolerability.
Children ages 1 to 17 weighing 20 to 45 kg: 20 mg PO t.i.d.
Children ages 1 to 17 weighing 20 kg or less: 10 mg PO t.i.d.
Released: April 2023
Nursing Drug Handbook
© 2023 Wolters Kluwer